Brief: Onxeo Announces Completion Of Enrollment In DRIIV-1b Study And Favorable Interim Results

Valerio Therapeutics SA

09/11/2020 17:18

Nov 9 (Reuters) - ONXEO SA  C4X.PA :
    * ANNOUNCED COMPLETION OF ENROLLMENT IN DRIIV-1B STUDY AND
FAVORABLE INTERIM RESULTS
    * LAST PATIENT WAS TREATED WITH ASIDNA™ IN COMBINATION WITH
CARBOPLATIN AND PACLITAXEL IN THIS PHASE 1B STUDY IN PATIENTS
WITH ADVANCED SOLID TUMORS
    * GOOD SAFETY PROFILE OF ASIDNA™ IS CONFIRMED TO DATE, WITH
NO
SERIOUS ADVERSE EVENTS RELATED TO ASIDNA™ AND NO DOSE-LIMITING
TOXICITIES OBSERVED
    * OF FIRST SEVEN PATIENTS, FOUR HAD A PARTIAL RESPONSE OR
LONGER
PERIODS OF CONTROL OF THEIR DISEASE THAN WITH PREVIOUS TREATMENT
LINES; THREE PATIENTS ARE STILL BEING TREATED
    * THESE PRELIMINARY DATA REPRESENT A PARTICULARLY
ENCOURAGING
SIGNAL OF EFFICACY AND SUPPORT FURTHER CLINICAL DEVELOPMENT OF
ASIDNA™ IN COMBINATION WITH THESE REFERENCE CHEMOTHERAPIES

Source text for Eikon:  ID:nGNX3wW7Vz 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))